Bruce E Johnson

Bruce E Johnson

UNVERIFIED PROFILE

Are you Bruce E Johnson?   Register this Author

Register author
Bruce E Johnson

Bruce E Johnson

Publications by authors named "Bruce E Johnson"

Are you Bruce E Johnson?   Register this Author

99Publications

3323Reads

34Profile Views

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later.

J Cell Biochem 2019 Dec 5. Epub 2019 Dec 5.

Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.29564DOI Listing
December 2019

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

J Thorac Oncol 2019 Sep 20;14(9):1666-1671. Epub 2019 Jun 20.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708730PMC
September 2019

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Oncologist 2019 Aug 29;24(8):e749-e754. Epub 2019 Jan 29.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0596DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693709PMC
August 2019

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Clin Cancer Res 2019 01 17;25(1):158-165. Epub 2018 Sep 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2062DOI Listing
January 2019

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Eur J Radiol 2018 Dec 23;109:68-76. Epub 2018 Oct 23.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2018.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294464PMC
December 2018

2018 ASCO Presidential Address: "Delivering Discoveries: Expanding the Reach of Precision Medicine".

Authors:
Bruce E Johnson

J Clin Oncol 2018 10 30;36(29):2899-2903. Epub 2018 Aug 30.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00535DOI Listing
October 2018

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.

J Thorac Oncol 2018 09 9;13(9):1400-1409. Epub 2018 May 9.

Department of Surgery, Division of General Thoracic Surgery, Baylor College of Medicine, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.032DOI Listing
September 2018

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Arch Pathol Lab Med 2018 07 12;142(7):796-797. Epub 2018 Apr 12.

From the Department of Medical Oncology, Gustave Roussy, Villejuif, France (Dr Planchard); and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, (Dr Johnson).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0088-EDDOI Listing
July 2018

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Cancer 2017 Nov 25;123(21):4099-4105. Epub 2017 Jul 25.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650517PMC
November 2017

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.

Eur J Radiol 2017 Mar 26;88:15-20. Epub 2016 Dec 26.

Department of Medical Oncology and Department of Medicine Dana-Farber Cancer Institute and Brigham and Women's Hospital 450 Brookline Ave., Boston MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2016.12.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560072PMC
March 2017

Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspective.

Ann Intern Med 2017 02;166(4):JC16

Virginia Tech Carilion School of MedicineRoanoke, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/ACPJC-2017-166-4-016DOI Listing
February 2017

Divide and Conquer to Treat Lung Cancer.

Authors:
Bruce E Johnson

N Engl J Med 2016 11 8;375(19):1892-1893. Epub 2016 Oct 8.

From the Department of Medical Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Brigham and Women's Hospital - both in Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1611003DOI Listing
November 2016

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

J Thorac Oncol 2016 Apr 25;11(4):556-65. Epub 2015 Dec 25.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.12.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979601PMC
April 2016

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Acad Radiol 2016 Mar 8;23(3):329-36. Epub 2016 Jan 8.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2015.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744559PMC
March 2016

Emerging gene mutation targets in lung cancer.

Authors:
Bruce E Johnson

Clin Adv Hematol Oncol 2015 Dec;13(12):812-4

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
December 2015

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Oncotarget 2015 Feb;6(6):4527-36

Department of Neurosciences, Translational Neuro-Oncology Laboratories, Moores UCSD Cancer Center, University of California, San Diego, La Jolla CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414209PMC
http://dx.doi.org/10.18632/oncotarget.2886DOI Listing
February 2015

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Lung Cancer 2014 Nov 27;86(2):241-6. Epub 2014 Aug 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293119PMC
November 2014

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

J Thorac Oncol 2014 Sep;9(9):1411-7

*University of California Los Angeles, Los Angeles, CA; †Kaiser Permanente Northern CA, Antioch, CA; ‡Sarah Cannon Research Institute, Nashville, TN; §Northwest Medical Specialties, Tacoma, WA; ‖Sibley Memorial Hospital, Washington, DC; ¶Integrated Community Oncology Network, Jacksonville, FL; #The Mark H. Zangmeister Center, Columbus, OH; **Florida Cancer Specialists, Bonita Springs, FL; ††Arch Medical Services Inc., The Center for Cancer Care and Research, Saint Louis, MO; ‡‡National Taiwan University, Taipei, Taiwan; §§F. Hoffmann-La Roche Ltd., Basel, Switzerland; ‖‖Genentech Inc., South San Francisco, CA; ¶¶Weill Cornell Medical College and Thoracic Oncology Service, New York, NY; and ##Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000274DOI Listing
September 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

J Natl Cancer Inst 2014 Aug 8;106(8). Epub 2014 Aug 8.

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (JJL, GRO, CPP, BEJ), Memorial Sloan-Kettering Cancer Center, New York, NY (DBS), University of Colorado Cancer Center, Denver, CO (DRC); The University of Texas MD Anderson Cancer Center, Houston, TX (JVH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281080PMC
August 2014

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

Int J Radiat Oncol Biol Phys 2014 Jul 24;89(4):880-7. Epub 2014 May 24.

Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2014.04.007DOI Listing
July 2014

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

J Natl Cancer Inst 2014 Jul 24;106(7). Epub 2014 Jun 24.

Affiliations of authors: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (SED); Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (GIS, BEJ); Department of Hematology and Oncology (JWC) and Department of Medicine (JWC), Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju163DOI Listing
July 2014

State of the art: Response assessment in lung cancer in the era of genomic medicine.

Radiology 2014 Apr;271(1):6-27

From the Departments of Imaging (M.N.) and Medical Oncology (B.E.J.), Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; Departments of Radiology (M.N., H.H.) and Medicine (B.E.J.), Brigham and Women's Hospital, Boston, Mass; and Department of Radiology, Massachusetts General Hospital, Boston, Mass (T.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.14122524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263630PMC
April 2014

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cancer Res 2013 Nov 24;73(22):6770-9. Epub 2013 Sep 24.

Authors' Affiliations: Departments of Medical Oncology and Cancer Biology; Center for Cancer Genome Discovery, Lowe Center for Thoracic Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of Medicine, Brigham and Women's Hospital; Departments of Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, Boston, Massachusetts; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea; and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903789PMC
November 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

J Clin Oncol 2013 Nov 7;31(31):3926-34. Epub 2013 Oct 7.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA; Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Chin-Yu Lin and Chris Bowden, Genentech, South San Francisco; Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA; John Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA; Bruce Kressel, Sibley Memorial Hospital, Washington, DC; Thomas Marsland, Integrated Community Oncology Network, Orange Park; Mark Rubin, Florida Cancer Specialists, Fort Myers, FL; Taral Patel, The Mark H. Zangmeister Center, Columbus, OH; Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO; Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; and James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.3983DOI Listing
November 2013

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

The impact of genomic changes on treatment of lung cancer.

Am J Respir Crit Care Med 2013 Oct;188(7):770-5

1 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201305-0843PPDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826273PMC
October 2013

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

AJR Am J Roentgenol 2013 Jul;201(1):W64-71

Department of Imaging Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.12.9668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731976PMC
July 2013

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

Cancer 2013 Jun 5;119(11):2048-60. Epub 2013 Apr 5.

Center for Patient Safety, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28022DOI Listing
June 2013

Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts.

J Natl Cancer Inst 2013 May 17;105(9):589-90. Epub 2013 Apr 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt085DOI Listing
May 2013

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(12):1767-1774

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182745bcbDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500523PMC
December 2012

Adjuvant chemotherapy for surgically resected non-small cell lung cancer.

J Thorac Cardiovasc Surg 2012 Sep 13;144(3):S39-42. Epub 2012 Apr 13.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 1234, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00225223120035
Publisher Site
http://dx.doi.org/10.1016/j.jtcvs.2012.03.039DOI Listing
September 2012

Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.

Risk Anal 2012 Jul;32 Suppl 1:S117-24

Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1539-6924.2011.01652.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478757PMC
July 2012

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Cancer Imaging 2012 Jun 29;12:225-35. Epub 2012 Jun 29.

Department of Radiology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1102/1470-7330.2012.0027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392782PMC
June 2012

Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.

Clin Cancer Res 2012 Feb;18(3):619-24

Nodality, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2017DOI Listing
February 2012

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer.

Cancer 2011 Jul 10;117(13):2961-9. Epub 2011 Jan 10.

Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314027PMC
July 2011

Imaging of lung cancer in the era of molecular medicine.

Acad Radiol 2011 Apr 28;18(4):424-36. Epub 2011 Jan 28.

Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2010.10.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380440PMC
April 2011

Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women.

Lung Cancer 2011 Mar 23;71(3):258-63. Epub 2010 Jul 23.

Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2010.06.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988987PMC
March 2011

Parity and risk of lung cancer in women.

Am J Epidemiol 2010 Mar 31;171(5):557-63. Epub 2010 Jan 31.

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/aje/kwp441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842216PMC
March 2010

ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal women.

Ann Intern Med 2010 Feb;152(4):JC-28

Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/0003-4819-152-4-201002160-02008DOI Listing
February 2010

The Intermountain Risk Score, based on common laboratory tests, was highly predictive of short-term mortality.

Authors:
Bruce E Johnson

Evid Based Med 2009 Dec;14(6):186

Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.

View Article

Download full-text PDF

Source
http://ebm.bmj.com/cgi/doi/10.1136/ebm.14.6.186
Publisher Site
http://dx.doi.org/10.1136/ebm.14.6.186DOI Listing
December 2009

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Clin Cancer Res 2009 Dec;15(24):7502-7509

Authors' Affiliations: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0189DOI Listing
December 2009

Integration of molecular profiling into the lung cancer clinic.

Clin Cancer Res 2009 Sep 25;15(17):5317-22. Epub 2009 Aug 25.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-09-0913DOI Listing
September 2009